Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Musculoskeletal Pain Market

DelveInsight’s ‘Musculoskeletal Pain – Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Musculoskeletal Pain in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Musculoskeletal Pain market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Musculoskeletal Pain market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current Musculoskeletal Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Musculoskeletal Pain: Disease Understanding and Treatment Algorithm

Musculoskeletal Pain Overview

Musculoskeletal pain (MSP) is defined as acute or chronic pain that affects bones, muscles, ligaments, tendons, and even nerves. Musculoskeletal pain (in particular, low back pain) is the main contributor to disability worldwide. According to the World Health Organization (WHO), 20–33% of the world’s population has some form of Musculoskeletal Pain, translating to 1.75 billion people globally.

 

Chronic pain is a complex, multifaceted phenomenon without a widely accepted definition. It has been defined as unremitting pain lasting >3 months or simply as “pain that extends beyond an expected period of healing.” The Pain Task Force of the (IASP) defines Chronic Primary Musculoskeletal Pain (CPMP) as “chronic pain” in the muscles, bones, joints, or tendons that are characterized by significant emotional distress (i.e., anxiety, anger, frustration, and depressed mood) or functional disability. Chronic low back pain, neck pain, and hip pain are the most common types, while disorders such as hip and knee osteoarthritis, and fibromyalgia are characterized by Musculoskeletal Pain.

 

Musculoskeletal pain is not purely nociceptive; peripheral inflammation, central sensitization processes, and neuropathic components also contribute.

 

NSAIDs are among the drugs most frequently recommended by orthopedic surgeons. NSAIDs and aspirin have analgesic, anti-inflammatory, and antipyretic properties and inhibit cyclooxygenase (COX). Acetaminophen has similar analgesic and antipyretic properties but lacks comparable anti-inflammatory effects. Although evidence indicates that these drugs have modest analgesic efficacy for acute musculoskeletal pain, they are markedly less effective for managing chronic pain conditions. The analgesic effects of NSAIDs and aspirin are related closely to their ability to decrease local inflammatory mediators.

 

In a large meta-analysis on the use of NSAIDs for lower back pain (LBP), the authors found that NSAIDs provided no greater relief of LBP than placebo. However, in clinical practice guidelines on the treatment of symptomatic osteoarthritis of the knee developed by the American Academy of Orthopedic Surgeons, selective, nonselective, and topical NSAIDs were recommended. Despite mixed evidence for the use of NSAIDs for chronic pain, many patients continue taking either prescribed or over-the-counter NSAID preparations. Prolonged use of these medications has been associated with adverse effects such as gastrointestinal (GI) complications, which both providers and patients recognize.

 

Morphine, the archetypal opiate, has often been considered the standard of care for analgesic management of pain. Despite the efficacy of morphine and its opioid analogs in the acute setting, these drugs generally have poor efficacy in the chronic pain setting. Gabapentin and pregabalin effectively treat patients with neuropathic pain and are approved in the United States for neuropathic pain conditions like spinal cord injury, shingles, and diabetic neuropathy. These medications have a more tolerable side-effect profile compared to other anticonvulsants. Tricyclic antidepressants (TCA) (e.g., amitriptyline and nortriptyline) have an analgesic effect that is independent of their antidepressant effect. The pharmacological actions of TCAs can be linked to their effect as a calcium channel antagonist, sodium channel antagonist, and their NMDA receptor antagonist effect. More specifically, the analgesic effect is believed to be due to the presynaptic reuptake inhibition of the monoamines such as serotonin and norepinephrine. Serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine 60–120 mg) should be considered to treat patients with various chronic pain conditions such as diabetic neuropathic pain, fibromyalgia, osteoarthritis, and LBP. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (20–80 mg) may also be considered to treat patients with fibromyalgia, although it has not been successful in treating several forms of neuropathic pain.

 

Companies such as Mesoblast, Mitsubishi Tanabe Pharma, Regeneron Pharmaceuticals, Ampio Pharmaceuticals, Charleston Laboratories, Sorrento Therapeutics, Centrexion Therapeutics, MDM S.p.A., Braeburn Pharmaceuticals, and Taiwan Liposome Company are actively involved in developing therapies for the treatment of MSP.  It is anticipated that with the launch of key assets like Ampion (Ampio Pharmaceuticals), CAM2038 (Braeburn Pharmaceuticals), CNTX-4975 (Centrexion Therapeutics), and fasinumab, the market size would witness expedited growth during the forecasted period.  

 

Musculoskeletal Pain Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Musculoskeletal Pain market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Musculoskeletal Pain market report thoroughly understands Musculoskeletal Pain by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Musculoskeletal Pain in the US, Europe, and Japan.

Musculoskeletal Pain Epidemiology

The Musculoskeletal Pain epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Musculoskeletal Pain epidemiology segmented as the Diagnosed Prevalent cases of Musculoskeletal Pain, Age-specific cases of Musculoskeletal Pain, and Gender-specific cases of Musculoskeletal Pain. The report includes the prevalent scenario of Musculoskeletal Pain in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Musculoskeletal Pain Epidemiology

The epidemiology segment also provides the Musculoskeletal Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The diagnosed prevalent population of Musculoskeletal Pain in the 7MM countries was estimated to be 145,426,730 cases in 2020.

Musculoskeletal Pain Drug Chapters

The drug chapter segment of the Musculoskeletal Pain report encloses the detailed analysis of Musculoskeletal pain marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the Musculoskeletal Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

A multimodal, multidisciplinary approach is required when managing patients with musculoskeletal pain. Non-opioid analgesics should be used first, and then opioids, with caution. Extended-release tramadol; selected tricyclic antidepressants, serotonin reuptake inhibitors, and anticonvulsants; and topical medications such as lidocaine, diclofenac, and capsaicin are among the most effective treatments.

 

It is expected that the therapeutic market size of Musculoskeletal Pain is expected to change significantly after the launch of various novel therapies, which include monoclonal antibodies (LY3016859),  stem cell therapies (Rexlemestrocel-L), and disease-modifying OA drug (DMOAD) like lorecivivint, TG-C in the market. Overall, the increasing prevalence, awareness of the disease, and promising emerging pipeline therapies will propel the market size during the forecast period of 2018–2030.

Products detail in the report…

 

Musculoskeletal pain emerging drugs

 

Rexlemestrocel-L/MPC-06-ID is a candidate for treating chronic low back pain (CLBP) caused by disc degeneration.  It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions. Mesoblast completed Phase III trial of rexlemestrocel-L for CLBP. The study evaluated the efficacy and safety of a single injection of rexlemestrocel-L alone or combined with Hyaluronic Acid (HA) in subjects with chronic low back pain. It was seen that a single injection of rexlemestrocel-L + HA carrier resulted in at least 2 years of pain reduction with opioid-sparing activity in patients with CLBP due to degenerative disc disease (DDD). Mesoblast has filed a request and expects to hold a Type C meeting with the US FDA to discuss the pathway to US regulatory approval for rexlemestrocel-L in patients with CLBP due to DDD (Mesoblast, 2021b).

 

Fasinumab/REGN475/MT-5547 is an investigational therapy invented by Regeneron using the company’s proprietary VelocImmune technology that yields optimized fully human antibodies. Fasinumab targets nerve growth factor (NGF), a protein that plays a central role in regulating pain signaling. There is evidence that NGF levels are elevated in the synovial fluid of patients with chronic pain conditions (Regeneron Pharmaceuticals, 2018). The drug has completed its evaluation in several trials for osteoarthritis. In August 2020, Regeneron announced that it had already obtained the core efficacy data to support potential fasinumab regulatory filings and continued to gather long-term safety data, which it expects to report in 2021, along with its decision on the program.

Products detail in the report…

Musculoskeletal Pain Market Outlook

The Musculoskeletal Pain market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Musculoskeletal Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Musculoskeletal Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

 

According to DelveInsight, the Musculoskeletal Pain market in the 7MM is expected to change in the study period 2018–2030.

 

ZILRETTA is the first and only extended-release, intra-articular therapy for patients confronting osteoarthritis-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide — a commonly administered, short-acting corticosteroid — with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief over 12 weeks. ZILRETTA received approval from the US Food and Drug Administration in October 2017, and the company initiated the full commercial launch in November 2017.

 

For knee pain, viscosupplements such as intra-articular hyaluronate injections were better than placebo for reducing pain and improving function in the short term (1–4 weeks). However, high clinical and statistical heterogeneity, evidence of publication bias, and low-quality trials preclude definitive recommendations about routine use in clinical practice. Furthermore, the available evidence did not suggest injections are effective for managing neck pain or back pain. Thus, this indicates that injections offer short-term pain relief for shoulder and knee pain, but the effectiveness of back and neck pain is uncertain.

 

JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Improvement of symptoms of osteoarthritis (knee joint and hip joint) is expected by administering JOYCLU into the joint cavity once every 4 weeks. Further, since JOYCLU is administered directly into the joint cavity as an injectable treatment, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is thought to be low. JOYCLU is the first joint function improvement agent in Japan indicated for treating osteoarthritis of the hip joint. In March 2021, Ono Pharmaceutical and Seikagaku Corporation announced that Seikagaku obtained from the Ministry of Health, Labour, and Welfare (MHLW) a manufacturing and marketing approval in Japan for JOYCLU 30 mg Intra-articular Injection. The drug is presently being evaluated in a Phase II trial in the US to treat knee osteoarthritis.

 

Cingal is a third-generation viscosupplement approved in the European Union to treat pain associated with osteoarthritis effectively. It is a powerful, first-in-class treatment that combines the benefits of Anika’s proprietary cross-linked hyaluronic acid formulation of Monovisc, proven to deliver up to 6 months of relief of the symptoms of osteoarthritis, with a well-established FDA-approved steroid to treat inflammation and provide additional short-term pain relief. In its pivotal clinical study, Cingal demonstrated an ability to provide fast and long-lasting pain relief for those affected by knee OA. The company plans to do NDA filing in 2026 for the US launch.

 

Key Findings

This section includes a glimpse of the Musculoskeletal Pain market in the 7MM. The market size of Musculoskeletal Pain in the seven major markets was USD 3,647.2 million in 2020.

 

The United States: Market Outlook

This section provides Musculoskeletal Pain market size and market size by therapies of Musculoskeletal Pain in the United States.

 

The United States accounts for the largest market size of Musculoskeletal Pain compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

As no individual therapy has demonstrated consistent benefit, a multimodal treatment approach to musculoskeletal pain is recommended.  These include non-pharmacological treatments (e.g., self-management advice and education, exercise therapy, manual therapy, and psychosocial interventions), complementary therapies (acupuncture), and pharmacological interventions (analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections. Surgical interventions, e.g., arthroscopic debridement, total knee replacements, and laminectomies, may be considered in patients with refractory symptoms.

 

Analgesics (oral and topical): Various studies, including pharmacological interventions for musculoskeletal pain, examined the effectiveness of analgesics (opioids and non-opioids) in the short and long-term as well as in acute and chronic pain presentations. NSAIDs and opioid analgesics (especially for acute pain) were generally effective, but beneficial effects were evident mainly in the short term. Cyclooxygenase (Cox)-2 selective inhibitors (e.g., celecoxib) were found to be effective for musculoskeletal pain relief. However, these were more likely to be associated with higher risks of adverse cardiovascular and gastrointestinal events than non-selective NSAIDs. In the long term and for more chronic pain presentations, stepwise analgesia may be recommended according to the WHO analgesic ladder (mostly based on expert opinion).

 

EU-5 Countries: Market Outlook

The total Musculoskeletal Pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

 

Japan Market Outlook

The total Musculoskeletal Pain market size and market size by therapies of Musculoskeletal Pain in Japan are also mentioned.

Musculoskeletal Pain Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Musculoskeletal Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Musculoskeletal Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Musculoskeletal Pain key players involved in developing targeted therapeutics.

 

Major players include Mesoblast, Mitsubishi Tanabe Pharma, Regeneron Pharmaceuticals, Ampio Pharmaceuticals, Charleston Laboratories, Sorrento Therapeutics, and others whose key products are expected to get launched in the US market by 20XX.

 

Pipeline Development Activities

The report covers collaborations, acquisition, merger, licensing, and patent details for Musculoskeletal Pain emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Musculoskeletal Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Musculoskeletal Pain market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Musculoskeletal Pain market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Musculoskeletal Pain, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Musculoskeletal Pain epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Musculoskeletal Pain is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Musculoskeletal Pain market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Musculoskeletal Pain market.

Report Highlights

  • In the coming years, the Musculoskeletal Pain market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Musculoskeletal Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Musculoskeletal Pain. The launch of emerging therapies will significantly impact the Musculoskeletal Pain market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Musculoskeletal Pain.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Musculoskeletal Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Musculoskeletal Pain Pipeline Analysis
  • Musculoskeletal Pain Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Musculoskeletal Pain Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Musculoskeletal Pain Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Musculoskeletal Pain Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Musculoskeletal Pain Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Musculoskeletal Pain total market Size and market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Musculoskeletal Pain market Size during the forecast period (2018–2030)?
  • At what CAGR, the Musculoskeletal Pain market is expected to grow in the 7MM during the forecast period (2018–2030)?
  • What would be the Musculoskeletal Pain market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Musculoskeletal Pain market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Musculoskeletal Pain?
  • What is the historical Musculoskeletal Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Musculoskeletal Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Musculoskeletal Pain?
  • Out of all 7MM countries, which country would have the highest Prevalence of Musculoskeletal Pain during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Musculoskeletal Pain?
  • What are the current treatment guidelines for treating Musculoskeletal Pain in the US, Europe, and Japan?
  • What are the Musculoskeletal pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Musculoskeletal Pain?
  • How many therapies are developed by each company for the treatment of Musculoskeletal Pain?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Musculoskeletal Pain?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Musculoskeletal Pain therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Musculoskeletal Pain and their status?
  • What are the key designations that have been granted for the emerging therapies for Musculoskeletal Pain?
  • What are the global historical and forecasted markets for Musculoskeletal Pain?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Musculoskeletal Pain market
  • To understand the future market competition in the Musculoskeletal Pain market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Musculoskeletal Pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Musculoskeletal Pain market.
  • To understand the future market competition in the Musculoskeletal Pain market.

1. Report Introduction

2. Musculoskeletal Pain Market Overview at a Glance

2.1. Market Share (%) Distribution of Musculoskeletal Pain in 2018

2.2. Market Share (%) Distribution of Musculoskeletal Pain in 2030

3. Executive Summary of Musculoskeletal Pain

4. Disease Background and Overview

4.1. Introduction

4.2. Types of Musculoskeletal Pain

4.3. Signs and Symptoms of Musculoskeletal Pain

4.4. Causes of Musculoskeletal Pain

4.5. Pathophysiology of Musculoskeletal Pain

4.6. Diagnosis of Musculoskeletal Pain

4.7. Biomarkers for Musculoskeletal Pain

4.8. Treatment of Musculoskeletal Pain

4.9. Guidelines for Management for Musculoskeletal pain

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total Diagnosed Prevalent cases of Musculoskeletal Pain

5.3. Epidemiology of Musculoskeletal Pain

5.4. The United States

5.4.1. Diagnosed prevalent cases of Musculoskeletal Pain in the United States

5.4.2. Age-specific Cases of Musculoskeletal Pain in the United States

5.4.3. Gender-specific Prevalence of Musculoskeletal Pain in the United States

5.5. EU5

5.5.1. Germany

5.5.1.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in Germany

5.5.1.2. Age-specific Cases of Musculoskeletal Pain in Germany

5.5.1.3. Gender-specific cases of Musculoskeletal Pain in Germany

5.5.2. France

5.5.2.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in France

5.5.2.2. Age-specific Cases of Musculoskeletal Pain in France

5.5.2.3. Gender-specific cases of Musculoskeletal Pain in France

5.5.3. Italy

5.5.3.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in Italy

5.5.3.2. Age-specific Cases of Musculoskeletal Pain in Italy

5.5.3.3. Gender-specific cases of Musculoskeletal Pain in Italy

5.5.4. Spain

5.5.4.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in Spain

5.5.4.2. Age-specific Cases of Musculoskeletal Pain in Spain

5.5.4.3. Gender-specific cases of Musculoskeletal Pain in Spain

5.5.5. The United Kingdom

5.5.5.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in the UK

5.5.5.2. Age-specific Cases of Musculoskeletal Pain in the UK

5.5.5.3. Gender-specific cases of Musculoskeletal Pain in the United Kingdom

5.6. Japan

5.6.1. Diagnosed Prevalent Cases of Musculoskeletal Pain in Japan

5.6.2. Age-specific Cases of Musculoskeletal Pain in Japan

5.6.3. Gender-specific cases of Musculoskeletal Pain in Japan

6. Organizations contributing towards the fight against Musculoskeletal Pain

7. Case Reports

8. Patient Journey

9. Marketed Products

9.1. Marketed Key Cross

9.2. Cymbalta: Eli Lilly and Company

9.2.1. Product Description

9.2.2. Regulatory Milestones

9.2.3. Safety and Efficacy

9.2.4. Side effects

9.2.5. Product Profile

9.3. Drizalma Sprinkle: Sun Pharma Global FZE

9.3.1. Product Description

9.3.2. Regulatory Milestones

9.3.3. Safety and Efficacy

9.3.4. Side effects

9.3.5. Product Profile

9.4. Zilretta: Flexion Therapeutics

9.4.1. Product Description

9.4.2. Regulatory Milestones

9.4.3. Safety and Efficacy

9.4.4. Side effects

9.4.5. Product Profile

9.5. Loqoa Tape: Taisho Pharmaceutical

9.5.1. Product Description

9.5.2. Regulatory Milestones

9.5.3. Side effects

9.5.4. Product Profile

9.6. Cingal: Anika Therapeutics

9.6.1. Product Description

9.6.2. Regulatory Milestones

9.6.3. Safety and Efficacy

9.6.4. Side effects

9.6.5. Product Profile

10. Emerging Drugs

10.1. Key Cross Competition

10.2. Rexlemestrocel-L (MPC-06-ID): Mesoblast

10.2.1. Drug Description

10.2.2. Other Development Activity

10.2.3. Clinical Development

10.2.4. Clinical trial information

10.2.5. Safety and efficacy

10.2.6. Product Profile

10.3. Fasinumab: Regeneron Pharmaceuticals|Teva Pharmaceutical Industries|Mitsubishi Tanabe Pharma

10.3.1. Drug Description

10.3.2. Other Development Activity

10.3.3. Clinical Development

10.3.4. Clinical trial information

10.3.5. Safety and efficacy

10.3.6. Product Profile

10.4. Resiniferatoxin: Sorrento Therapeutics

10.4.1. Drug Description

10.4.2. Clinical Development

10.4.3. Clinical trial information

10.4.4. Safety and efficacy

10.4.5. Product Profile

10.5. TLC599: Taiwan Liposome Company

10.5.1. Drug Description

10.5.2. Clinical Development

10.5.3. Clinical trial information

10.5.4. Safety and efficacy

10.5.5. Product Profile

10.6. LY3556050: Eli Lilly and Company

10.6.1. Drug Description

10.6.2. Clinical Development

10.6.3. Clinical trial information

10.6.4. Product Profile

10.7. LY3016859: Eli Lilly and Company

10.7.1. Drug Description

10.7.2. Clinical Development

10.7.3. Clinical trial information

10.7.4. Product Profile

10.8. Esreboxetine (AXS-14): Axsome Therapeutics

10.8.1. Drug Description

10.8.2. Other Development Activities

10.8.3. Clinical Development

10.8.4. Clinical trial information

10.8.5. Safety and Efficacy

10.8.6. Product Profile

10.9. Lorecivivint: Biosplice Therapeutics

10.9.1. Drug Description

10.9.2. Clinical Development

10.9.3. Clinical trial information

10.9.4. Safety and Efficacy

10.9.5. Product Profile

10.10. CNTX-4975: Centrexion Therapeutics

10.10.1. Drug Description

10.10.2. Other Developmental Activities

10.10.3. Clinical Development

10.10.4. Clinical trial information

10.10.5. Safety and Efficacy

10.10.6. Product Profile

10.11. Ampion: Ampio Pharmaceuticals

10.11.1. Drug Description

10.11.2. Other Development Activities

10.11.3. Clinical Development

10.11.4. Clinical trial information

10.11.5. Safety and Efficacy

10.11.6. Product Profile

10.12. X0002: Techfields Pharma

10.12.1. Drug Description

10.12.2. Other Development Activity

10.12.3. Clinical Development

10.12.4. Clinical Information

10.12.5. Product Profile

10.13. IMC-1: Virios Therapeutics

10.13.1. Drug Description

10.13.2. Other Development activity

10.13.3. Clinical Development

10.13.4. Clinical Information

10.13.5. Safety and Efficacy

10.13.6. Product Profile

10.14. Buprenorphine/CAM2038: Camurus/Braeburn Pharmaceuticals

10.14.1. Drug Description

10.14.2. Other Development Activity

10.14.3. Clinical Development

10.14.4. Clinical trial Information

10.14.5. Safety and Efficacy

10.14.6. Product Profile

10.15. TG-C/INVOSSA/Tonogenchoncel-L: Kolon TissueGene

10.15.1. Drug Description

10.15.2. Other Development Activity

10.15.3. Clinical Development

10.15.4. Clinical Information

10.15.5. Safety and Efficacy

10.15.6. Product Profile

10.16. AMZ001: Amzell

10.16.1. Drug Description

10.16.2. Clinical Development

10.16.3. Clinical trial information

10.16.4. Safety and Efficacy

10.16.5. Product Profile

10.17. JOYCLU: Seikagaku Corporation

10.17.1. Drug Description

10.17.2. Other Development Activities

10.17.3. Clinical Development

10.17.4. Clinical trial information

10.17.5. Safety and Efficacy

10.17.6. Product Profile

11. Other Assets in Development

11.1. Other Assets Key Cross

11.2. Fremanezumab: Teva Pharmaceutical Industries

11.2.1. Drug Description

11.2.2. Clinical Development

11.2.3. Clinical trial information

11.2.4. Product Profile

11.3. CGS-200-5: Propella Therapeutics

11.3.1. Drug Description

11.3.2. Clinical Development

11.3.3. Clinical trial information

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. DFV890: Novartis Pharmaceuticals

11.4.1. Drug Description

11.4.2. Other Development Activity

11.4.3. Clinical Development

11.4.4. Clinical trial information

11.4.5. Product Profile

11.5. Canakinumab: Novartis Pharmaceuticals

11.5.1. Drug Description

11.5.2. Clinical Development

11.5.3. Clinical trial information

11.5.4. Product Profile

11.6. MM-II: Sun Pharmaceutical Industries|Moebius Medical

11.6.1. Drug Description

11.6.2. Other Development Activities

11.6.3. Clinical Development

11.6.4. Clinical trial information

11.6.5. Safety and Efficacy

11.6.6. Product Profile

11.7. Otenaproxesul/ATB-346: Antibe Therapeutics

11.7.1. Drug Description

11.7.2. Clinical Development

11.7.3. Clinical Information

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. NOVOCART 3D: Aesculap Biologics

11.8.1. Drug Description

11.8.2. Clinical Development

11.8.3. Clinical Information

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. StroMed + platelet-rich plasma (PRP): VivaTech

11.9.1. Drug Description

11.9.2. Clinical Development

11.9.3. Clinical Information

11.9.4. Product Profile

11.10. XT-150: Xalud Therapeutics

11.10.1. Drug Description

11.10.2. Clinical Development

11.10.3. Clinical trial information

11.10.4. Product Profile

11.11. TNX-102 SL: Tonix Pharmaceuticals

11.11.1. Drug Description

11.11.2. Clinical Development

11.11.3. Clinical trial information

11.11.4. Safety and efficacy

11.11.5. Product Profile

11.12. ACP-044: ACADIA Pharmaceuticals

11.12.1. Drug Description

11.12.2. Other Development Activities

11.12.3. Clinical Development

11.12.4. Clinical trial information

11.12.5. Safety and Efficacy

11.12.6. Product Profile

11.13. MEDI7352: AstraZeneca

11.13.1. Drug Description

11.13.2. Clinical Development

11.13.3. Clinical trial information

11.13.4. Safety and Efficacy

11.13.5. Product Profile

11.14. CL-108: Charleston Laboratories

11.14.1. Drug Description

11.14.2. Other Developmental Activities

11.14.3. Clinical Development

11.14.4. Clinical trial information

11.14.5. Safety and Efficacy

11.14.6. Product Profile

12. Musculoskeletal Pain: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Size of Musculoskeletal Pain in 7MM

12.3. Market Outlook

12.4. The United States Market Size

12.4.1. Total Market Size of Musculoskeletal Pain in the United States

12.4.2. Market Size of Musculoskeletal Pain by Therapies in the US

12.5. EU-5 Market

12.5.1. Germany

12.5.1.1. Total Market Size of Musculoskeletal Pain in Germany

12.5.1.2. Market Size of Musculoskeletal Pain by Therapies in Germany

12.5.2. France

12.5.2.1. Total Market Size of Musculoskeletal Pain in France

12.5.2.2. Market Size of Musculoskeletal Pain by Therapies in France

12.5.3. Italy

12.5.3.1. Total Market Size of Musculoskeletal Pain in Italy

12.5.3.2. Market Size of Musculoskeletal Pain by Therapies in Italy

12.5.4. Spain

12.5.4.1. Total Market Size of Musculoskeletal Pain in Spain

12.5.4.2. Market Size of Musculoskeletal Pain by Therapies in Spain

12.5.5. The United Kingdom

12.5.5.1. Total Market Size of Musculoskeletal Pain in the United Kingdom

12.5.5.2. Market Size of Musculoskeletal Pain by Therapies in the United Kingdom

12.6. Japan Market Size

12.6.1. Total Market Size of Musculoskeletal Pain in Japan

12.6.2. Market Size of Musculoskeletal Pain by Therapies in Japan

13. Market Access

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. KOL Views

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of Musculoskeletal Pain, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Differences between acute and chronic pain

Table 3: List of different Adjuvant drugs used in musculoskeletal pain

Table 4: Grading the certainty of evidence and strength of recommendations of ACP clinical guidelines using GRADE.

Table 5: Diagnosed Prevalence of Musculoskeletal Pain in the 7MM (2018–2030)

Table 6: Diagnosed Prevalent Cases of Musculoskeletal Pain in the United States (2018–2030)

Table 7: Age-specific Cases of Musculoskeletal Pain in the United States (2018–2030)

Table 8: Gender-specific Prevalence of Musculoskeletal Pain in the United States (2018–2030)

Table 9: Diagnosed Prevalent Cases of Musculoskeletal Pain in Germany (2018–2030)

Table 10: Age-specific Cases of Musculoskeletal Pain Germany (2018–2030)

Table 11: Gender-specific cases of Musculoskeletal Pain in Germany (2018–2030)

Table 12: Diagnosed Prevalent Cases of Musculoskeletal Pain in France (2018–2030)

Table 13: Age-specific Cases of Musculoskeletal Pain in France (2018–2030)

Table 14: Gender-specific cases of Musculoskeletal Pain in France (2018–2030)

Table 15: Diagnosed Prevalent Cases of Musculoskeletal Pain in Italy (2018–2030)

Table 16: Age-specific Cases of Musculoskeletal Pain in Italy (2018–2030)

Table 17: Gender-specific cases of Musculoskeletal Pain in Italy (2018–2030)

Table 18: Diagnosed Prevalent Cases of Musculoskeletal Pain in Spain (2018–2030)

Table 19: Age-specific Cases of Musculoskeletal Pain in Spain (2018–2030)

Table 20: Gender-specific cases of Musculoskeletal Pain in Spain (2018–2030)

Table 21: Diagnosed Prevalent Cases of Musculoskeletal Pain in the UK (2018–2030)

Table 22: Age-specific Cases of Musculoskeletal Pain in the UK (2018–2030)

Table 23: Gender-specific cases of Musculoskeletal Pain in the UK (2018–2030)

Table 24: Diagnosed Prevalent Cases of Musculoskeletal Pain in Japan (2018–2030)

Table 25: Age-specific Cases of Musculoskeletal Pain in Japan (2018–2030)

Table 26: Gender-specific cases of Musculoskeletal Pain in Japan (2018–2030)

Table 27: Organizations contributing toward the fight against Musculoskeletal Pain

Table 28: Key cross of the Marketed drugs

Table 29: Dosage and Administration

Table 30: Dosage and Administration

Table 31: Key cross of emerging drugs

Table 32: Key cross of emerging drugs

Table 33: Key cross of emerging drugs

Table 34: Rexlemestrocel-L, Clinical Trial Description, 2021

Table 35: Fasinumab, Clinical Trial Description, 2021

Table 36: Resiniferatoxin, Clinical Trial Description, 2021

Table 37: TLC599, Clinical Trial Description, 2021

Table 38: LY3556050, Clinical Trial Description, 2021

Table 39: LY3016859, Clinical Trial Description, 2021

Table 40: Esreboxetine, Clinical Trial Description, 2021

Table 41: Lorecivivint, Clinical Trial Description, 2021

Table 42: CNTX-4975, Clinical Trial Description, 2021

Table 43: Ampion, Clinical Trial Description, 2021

Table 44: X0002, Clinical Trial Description, 2021

Table 45: IMC-1, Clinical Trial Description, 2021

Table 46: CAM2038, Clinical Trial Description, 2021

Table 47: TG-C, Clinical Trial Description, 2021

Table 48: AMZ001, Clinical Trial Description, 2021

Table 49: JOYCLU, Clinical Trial Description, 2021

Table 50: Key cross of Other Assets

Table 51: Key cross of Other Assets

Table 52: Fremanezumab, Clinical Trial Description, 2021

Table 53: CGS-200-5 Vehicle, Clinical Trial Description, 2021

Table 54: DFV890, Clinical Trial Description, 2021

Table 55: Canakinumab, Clinical Trial Description, 2021

Table 56: MM-II, Clinical Trial Description, 2021

Table 57: Ostenaproxesul, Clinical Trial Description, 2021

Table 58: NOVOCART 3D, Clinical Trial Description, 2021

Table 59: StroMed + platelet-rich plasma (PRP), Clinical Trial Description, 2021

Table 60: XT-150, Clinical Trial Description, 2021

Table 61: TNX-102 SL, Clinical Trial Description, 2021

Table 62: ACP-044, Clinical Trial Description, 2021

Table 63: MEDI7352, Clinical Trial Description, 2021

Table 64: CL-108, Clinical Trial Description, 2021

Table 65: Seven Major Market Size of Musculoskeletal Pain in USD Million (2018–2030)

Table 66: Market Size of Musculoskeletal Pain in the United States in USD Million (2018–2030)

Table 67: The US Market Size of Musculoskeletal Pain by Therapies in USD Million (2018–2030)

Table 68: Market Size of Musculoskeletal Pain in Germany in USD Million (2018–2030)

Table 69: Market Size of Musculoskeletal Pain by Therapies in Germany in USD Million (2018–2030)

Table 70: Market Size of Musculoskeletal Pain in France in USD Million (2018–2030)

Table 71: Market Size of Musculoskeletal Pain by Therapies in France USD Million (2018–2030)

Table 72: Market Size of Musculoskeletal Pain in Italy in USD Million (2018–2030)

Table 73: Market Size of Musculoskeletal Pain by Therapies in Italy in USD Million (2018–2030)

Table 74: Market Size of Musculoskeletal Pain in Spain in USD Million (2018–2030)

Table 75: The Spain Market Size of Musculoskeletal Pain by Therapies in USD Million (2018–2030)

Table 76: Market Size of Musculoskeletal Pain in the United Kingdom in USD Million (2018–2030)

Table 77: The United Kingdom Market Size of Musculoskeletal Pain by Therapies in USD Million (2018–2030)

Table 78: Market Size of Musculoskeletal Pain in Japan in USD Million (2018–2030)

Table 79: Market Size of Musculoskeletal Pain in Japan by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Different types of Musculoskeletal Pain

Figure 2: Signs and Symptoms of Musculoskeletal Pain

Figure 3: Schematic representation of the contribution of mast cells and microglia to degenerative joint diseases and neuro-inflammation.

Figure 4: Organization of bone innervation of the periosteum, cortical bone, and marrow

Figure 5: Joint and muscle innervation

Figure 6: Diagnosis algorithm of musculoskeletal complaints.

Figure 7: Pain Intensity Assessment Scales

Figure 8: WHO analgesic ladder for Musculoskeletal Pain

Figure 9: Step-care approach for treatment for osteoarthritis

Figure 10: Knee osteoarthritis treatment algorithm

Figure 11: Treatment algorithm for Musculoskeletal Pain

Figure 12: Total Diagnosed Prevalent Population of Musculoskeletal Pain in 7MM (2018–2030)

Figure 13: Diagnosed Prevalent Cases of Musculoskeletal Pain in the United States (2018–2030)

Figure 14: Age-specific Cases of Musculoskeletal Pain in the United States (2018–2030)

Figure 15: Gender-specific Prevalence of Musculoskeletal Pain in the United States (2018–2030)

Figure 16: Diagnosed Prevalent Cases of Musculoskeletal Pain in Germany (2018–2030)

Figure 17: Age-specific Cases of Musculoskeletal Pain in Germany (2018–2030)

Figure 18: Gender-specific cases of Musculoskeletal Pain in Germany (2018–2030)

Figure 19: Diagnosed Prevalent Cases of Musculoskeletal Pain in France (2018–2030)

Figure 20: Age-specific Cases of Musculoskeletal Pain in France (2018–2030)

Figure 21: Gender-specific cases of Musculoskeletal Pain in France (2018–2030)

Figure 22: Diagnosed Prevalent Cases of Musculoskeletal Pain in Italy (2018–2030)

Figure 23: Age-specific Cases of Musculoskeletal Pain in Italy (2018–2030)

Figure 24: Gender-specific cases of Musculoskeletal Pain in Italy (2018–2030)

Figure 25: Diagnosed Prevalent Cases of Musculoskeletal Pain in Spain (2018–2030)

Figure 26: Age-specific Cases of Musculoskeletal Pain in Spain (2018–2030)

Figure 27: Gender-specific cases of Musculoskeletal Pain in Spain (2018–2030)

Figure 28: Diagnosed Prevalent Cases of Musculoskeletal Pain in the UK (2018–2030)

Figure 29: Age-specific Cases of Musculoskeletal Pain in the UK (2018–2030)

Figure 30: Gender-specific cases of Musculoskeletal Pain in the UK (2018–2030)

Figure 31: Diagnosed Prevalent Cases of Musculoskeletal Pain in Japan (2018–2030)

Figure 32: Age-specific Cases of Musculoskeletal Pain in Japan (2018–2030)

Figure 33: Gender-specific cases of Musculoskeletal Pain in Japan (2018–2030)

Figure 34: Seven Major Market Size of Musculoskeletal Pain in USD Million (2018–2030)

Figure 35: Market Size of Musculoskeletal Pain in the United States in USD Million (2018–2030)

Figure 36: Market Size of Musculoskeletal Pain in the United States by Therapies (2018–2030)

Figure 37: Market Size of Musculoskeletal Pain in Germany in USD Million (2018–2030)

Figure 38: Market Size of Musculoskeletal Pain in Germany by Therapies (2018–2030)

Figure 39: Market Size of Musculoskeletal Pain in France in USD Million (2018–2030)

Figure 40: Market Size of Musculoskeletal Pain in France by Therapies (2018–2030)

Figure 41: Market Size of Musculoskeletal Pain in Italy in USD Million (2018–2030)

Figure 42: Market Size of Musculoskeletal Pain in Italy by Therapies (2018–2030)

Figure 43: Market Size of Musculoskeletal Pain in Spain in USD Million (2018–2030)

Figure 44: Market Size of Musculoskeletal Pain in Spain by Therapies (2018–2030)

Figure 45: Market Size of Musculoskeletal Pain in the United Kingdom in USD Million (2018–2030)

Figure 46: Market Size of Musculoskeletal Pain in the United Kingdom by Therapies (2018–2030)

Figure 47: Market Size of Musculoskeletal Pain in Japan in USD Million (2018–2030)

Figure 48: Market Size of Musculoskeletal Pain in Japan by Therapies (2018–2030)

 

Eli Lilly and Company
Sun Pharma Global FZE
Flexion Therapeutics
Taisho Pharmaceutical
Anika Therapeutics
Mesoblast
Regeneron Pharmaceutical
Teva Pharmaceutical Industries
Mitsubishi Tanabe Pharma
Sorrento Therapeutics
Taiwan Liposome Company
Axsome Therapeutics
Biosplice Therapeutics
Centrexion Therapeutics
Ampio Pharmaceuticals
Techfields Pharma
Virios Therapeutics
Camurus
Braeburn Pharmaceuticals
Kolon TissueGene
Amzell
Seikagaku Corporation
Propella Therapeutics
Novartis Pharmaceuticals
Moebius Medical
Antibe Therapeutics
Aesculap Biologics
VivaTech
Xalud Therapeutics
Tonix Pharmaceuticals
ACADIA Pharmaceuticals
AstraZeneca
Charleston Laboratories

 

Forward to Friend

Need A Quote